Vaccine development for mosquito-borne viral diseases

Frontiers in Immunology

Immunology

Yanjun Zhang¹  Zhiwei Huang²  Yongliang Lou²  Wanchen Song³  Hongyu Li⁴  Jiajie Zhu⁴  Keda Chen⁴  Yuxuan Zhang⁴ 

[1] Department of Microbiology, Zhejiang Provincial Center for Disease Control and Prevention, Hangzhou, China;School of Laboratory Medicine and Life Sciences, Wenzhou Medical University, Wenzhou, China;School of Medical Technology and Information Engineering, Zhejiang Chinese Medical University, Hangzhou, China;Shulan International Medical College, Zhejiang Shuren University, Hangzhou, China;

关键词: vaccine;    Zika virus;    Chikungunya virus;    dengue virus;    mosquito-borne viral disease;   

DOI  :  10.3389/fimmu.2023.1161149

 received in 2023-02-07, accepted in 2023-04-13,  发布年份 2023

来源: Frontiers

【 摘 要 】

Mosquito-borne viral diseases are a group of viral illnesses that are predominantly transmitted by mosquitoes, including viruses from the Togaviridae and Flaviviridae families. In recent years, outbreaks caused by Dengue and Zika viruses from the Flaviviridae family, and Chikungunya virus from the Togaviridae family, have raised significant concerns for public health. However, there are currently no safe and effective vaccines available for these viruses, except for CYD-TDV, which has been licensed for Dengue virus. Efforts to control the transmission of COVID-19, such as home quarantine and travel restrictions, have somewhat limited the spread of mosquito-borne viral diseases. Several vaccine platforms, including inactivated vaccines, viral-vector vaccines, live attenuated vaccines, protein vaccines, and nucleic acid vaccines, are being developed to combat these viruses. This review analyzes the various vaccine platforms against Dengue, Zika, and Chikungunya viruses and provides valuable insights for responding to potential outbreaks.

【 授权许可】

Unknown   
Copyright © 2023 Huang, Zhang, Li, Zhu, Song, Chen, Zhang and Lou